PASG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Passage Bio Inc (PASG) is not a good buy for a beginner investor with a long-term investment strategy at this time. The company faces significant financial challenges, with deteriorating cash reserves and no revenue growth. Additionally, technical indicators and trading trends do not suggest a strong entry point. Analysts have lowered price targets significantly, and there are no strong positive catalysts to offset the risks.
The MACD is slightly positive but contracting, RSI is neutral at 35.954, and moving averages are converging, indicating no clear trend. Key support is at 7.932, and resistance is at 9.559. The stock is trading pre-market at $8.26, slightly above support levels but with no strong upward momentum.
The company has cash reserves expected to fund operations through Q1 2027, providing some runway for business adjustments.
Significant financial challenges with a GAAP EPS of -$4.09 for Q4 2025, cash reserves declining from $76.8M in 2024 to $46.3M in 2025, and no revenue growth. Analysts have lowered price targets significantly, and there are no recent positive trading trends or congress trading data.
In Q4 2025, the company reported a net income of -$12.98M, a slight improvement of 2.03% YoY. However, EPS dropped to -4.08, down 0.73% YoY, and revenue remains at $0 with no growth. Gross margin is also at 0%.
Canaccord analyst Whitney Ijem recently lowered the price target from $67 to $23, maintaining a Buy rating but reflecting reduced confidence due to challenges in the company's lead programs.
